![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ImmunoGen Inc | NASDAQ:IMGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 31.235 | 32.80 | 29.67 | 0 | 01:00:00 |
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that 11 posters highlighting continued innovation in the field of ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, Georgia.
“ImmunoGen remains at the forefront of ADC innovation and the data to be presented at AACR further demonstrate the value of our productive research platform,” said Richard Gregory, Ph.D., ImmunoGen’s chief scientific officer.
The schedule of ImmunoGen’s presentations at AACR is as follows:
IGN Payload Innovation
Title: Antibody-drug conjugates (ADCs) of a new class of N-10 amino linked DNA alkylating indolino-benzodiazepines (IGNs) – abstract #224Date: March 31, 2019Time: 1:00-5:00 PM ET
Title: Antibody-drug conjugates (ADCs) with indolinobenzodiazepine dimer (IGN) payloads: DNA-binding mechanism of IGN catabolites in target cancer cells - abstract #1886Date: March 31, 2019Time: 1:00-5:00 PM ET
Advancement in Platform Linkers and Payloads
Title: Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers - abstract #0231Date: March 31, 2019Time: 1:00-5:00 PM ET
Title: LC-MS based catabolite identification study of an ADC with DM21-C, a novel maytansinoid linker-payload - abstract #538Date: March 31, 2019Time: 1:00-5:00 PM ET
Title: Preclinical evaluation of DM21, a next‐generation maytansinoid payload with a stable peptide linker - abstract #3898Date: April 2, 2019Time: 1:00-5:00 PM ET
Novel Approaches to ADC Development
Title: Generation of site-specific DARPin® drug conjugates using EGFR as a model system - abstract #215Date: March 31, 2019Time: 1:00-5:00 PM ET
Title: Development of a Probody-Drug Conjugate (PDC) targeting EpCAM for the treatment of solid tumors - abstract #1439Date: March 31, 2019Time: 1:00-5:00 PM ET
Title: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity - abstract #5136Date: April 1, 2019Time: 8:00 AM-12:00 PM ET
Title: Preclinical evaluation of a new, non-agonist ADC targeting MET-amplified tumors with a peptide-linked maytansinoid - abstract #4817Date: April 3, 2019Time: 8:00 AM-12:00 PM ET
Optimizing ADC Dosing
Title: The potential benefit of lower drug-antibody ratio (DAR) on antibody-maytansinoid conjugate in vivo efficacy - abstract #219Date: March 31, 2019Time: 1:00-5:00 PM
Title: Utilizing a mouse cross-reactive model system to better understand antibody-drug conjugate pharmacokinetics, biodistribution and efficacy - abstract #229Date: March 31, 2019Time: 1:00-5:00 PM ET
Additional information and full abstracts can be found at www.aacr.org.
ABOUT IMMUNOGENImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
DARPin® is a registered trademark of Molecular Partners AG.PROBODY™ is a trademark of CytomX Therapeutics, Inc.
This press release includes forward-looking statements based on management's current expectations. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results, and the potential that earlier clinical studies may not be predictive of future results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and other reports filed with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190227005968/en/
INVESTOR RELATIONS CONTACTSarah Kiely781-895-0600sarah.kiely@immunogen.comMEDIA CONTACTCourtney O’Konek781-895-0600courtney.okonek@immunogen.comORFTI ConsultingRobert Stanislaro212-850-5657robert.stanislaro@fticonsulting.com
1 Year ImmunoGen Chart |
1 Month ImmunoGen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions